Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®.....»»

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases.....»»

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review.....»»

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016.....»»

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD.....»»

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease.....»»

Suven Life gets patents in Europe, Israel for neuro-degenerative drug candidate.....»»

Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic Response at Week 12 in Patientswith Active Crohn's Disease.....»»

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016.....»»

Bharat Biotech’s Zika vaccine ready to enter phase-1 trial.....»»

Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003).....»»